Vergent Bioscience

Biotechnology ResearchMinnesota, United States11-50 Employees

Vergent Bioscience is a clinical-stage biotechnology company based in Minneapolis, Minnesota, focused on improving tumor visibility during surgery. Its lead investigational agent, abenacianine for injection (VGT-309), is a tumor-targeted fluorescent imaging agent intended to help surgeons identify tumors in real time across open, laparoscopic, and robotic-assisted procedures, with initial evaluation in lung cancer and potential expansion to other solid tumors. The product is investigational and has not been approved by the FDA.

The company operates in the biotechnology research industry, aiming to address the demand for advanced visualization in oncologic surgeries. In January 2025, Vergent Bioscience received FDA Fast Track designation for abenacianine for injection to aid visualization of lung tumors during surgery. Earlier, the company announced Phase 2 data for VGT-309 and launched the VISUALIZE Phase 2 study in lung cancer surgeries, indicating ongoing development in solid tumors.

Sign up for free to view info

Email Format Employee directory